+39 02 610346.1 - info@newron.com

Success in CNS drug development – Innovation in Rare Diseases

We are a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Our shares are listed on the SIX Swiss Exchange (NWRN).

Latest press releases

  • 12Sep
    Newron reports half-year 2019 results

     

  • 10Jul
    Newron’s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv® (safinamide) for Parkinson’s disease in Canada

     

  • 28Jun
    Newron Receives First Tranche from Financing Agreement with European Investment Bank (EIB)

     

  • 27Jun
    Newron Pharmaceuticals now also listed on the primary market of the Düsseldorf Stock Exchange and on XETRA

     

  • 13Jun
    Newron Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

  • 28May
    Newron Pharmaceuticals provides update on regulatory status of evenamide for the treatment of schizophrenia

     

View All

Newron share price

Events

  • 18Sep
    Investora Zürich 2019

    September 18-19, 2019 - Samsung Hall, Dübendorf, Switzerland

  • 8Sep
    21st Annual Healthcare Conference, sponsored by H.C. Wainwright

    September 8-10, 2019 - The Lotte New York Palace Hotel, New York, USA

  • 19Jun
    JMP Securities Life Sciences Conference

    June 19-20, 2019 - The St. Regis New York, New York City, USA

View Event Calendar